Publication: Heparin-Bridging Therapy and Risk of Bleeding After Endoscopic Submucosal Dissection for Gastric Neoplasms: a Meta-Analysis
Issued Date
2018-03-01
Resource Type
ISSN
19416636
19416628
19416628
Other identifier(s)
2-s2.0-85041534434
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Gastrointestinal Cancer. Vol.49, No.1 (2018), 16-20
Suggested Citation
Veeravich Jaruvongvanich, Tomoki Sempokuya, Karn Wijarnpreecha, Patompong Ungprasert Heparin-Bridging Therapy and Risk of Bleeding After Endoscopic Submucosal Dissection for Gastric Neoplasms: a Meta-Analysis. Journal of Gastrointestinal Cancer. Vol.49, No.1 (2018), 16-20. doi:10.1007/s12029-017-0049-0 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46913
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Heparin-Bridging Therapy and Risk of Bleeding After Endoscopic Submucosal Dissection for Gastric Neoplasms: a Meta-Analysis
Abstract
© 2018, Springer Science+Business Media, LLC, part of Springer Nature. Purpose: Peri-procedural heparin is recommended as bridging therapy for patients with high thromboembolic risk who need to withhold anticoagulant for endoscopic submucosal dissection (ESD) for gastric neoplasms. However, little is known about the bleeding risk from heparin-bridging therapy itself. Methods: MEDLINE and EMBASE databases were searched through August 2017 for studies that compared the risk of post-ESD bleeding in patients who received heparin-bridging therapy in lieu of anticoagulant for gastric neoplasms and those who discontinued anticoagulant without receiving heparin. Pooled risk ratio (RR) and 95% confidence interval (CI) were calculated using a random-effect model, generic inverse variance method. The between-study heterogeneity was quantified using the Q statistic and I 2 . Results: A total of four studies consisting of 350 patients were identified. A significantly increased risk of post-ESD bleeding among the bridged patients compared with the non-bridged patients was observed with the pooled RR of 2.99 (95% CI, 1.51 to 5.92). The statistical heterogeneity was insignificant with I 2 of 0%. Conclusions: A significantly increased risk of post-ESD bleeding among patients who received heparin-bridging therapy in lieu of anticoagulant compared to patients who did not receive it was demonstrated in this study.